Company intelligence / Profile preview

EpiAxis Therapeutics

Bruce, Australian Capital Territory, Australiaepiaxistherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company has demonstrated clinical proof-of-concept in its Phase 1 trial ("EPIAXIS PRIMED"), validating the therapeutic potential of inhibiting LSD1 to reprogram dormant cancer cells and reinvigorate exhausted immune cells. This supports their dual-action mechanism for preventing recurrence and overcoming resistance. Further development continues with additional IP filings and expansion into new targets.

Therapeutic areas: Oncology
Modalities: Small molecules (notably LSD1 inhibitors)
Industry: Biotech

Partnerships

University Health Network (UHN), Canada’s largest research hospital—for collaborative research into prostate cancer treatment approaches.

Beyond the preview

Go deeper on EpiAxis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiAxis Therapeutics.

Explore the full profile